<DOC>
	<DOCNO>NCT00715663</DOCNO>
	<brief_summary>This study conduct Asia . The aim observational study evaluate safety , efficacy convenience use NovoMix® 30 FlexPen® type 2 diabetes normal clinical practice condition .</brief_summary>
	<brief_title>Observational Study Evaluate Safety , Efficacy Convenience Using NovoMix® 30 FlexPen® Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>All patient type 2 diabetes , adequately control current therapy , prescribe NovoMix® 30 FlexPen® monotherapy , combination OHA , accordance approve labeling , eligible survey .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>